Summary of Whitehawk Therapeutics FY Conference Call Company Overview - Company: Whitehawk Therapeutics (NasdaqCM:AADI) - Focus: Development of antibody-drug conjugates (ADCs) targeting various oncology indications, including lung cancer and gynecological cancers [1][2] Strategic Focus and Pipeline - ADC Candidates: Three clinical-stage ADC candidates licensed from WuXi Biologics, with plans to enter the clinic within the next six to nine months [2][3] - Partnership: Licensing agreement with WuXi Biologics valued at $46 million upfront, with an additional $90 million in development and approval milestones for each asset [4][5] Targeted Programs 1. HWK-007 (PTK7 Directed ADC): - Target: PTK7, a broadly overexpressed tumor antigen with potential applications in lung cancer and gynecological cancers [8][11] - Competitive Landscape: Opportunity to be first or second to market due to limited competition [1] 2. HWK-016 (MUC16 Targeting ADC): - Target: MUC16, associated with the biomarker CA125, prevalent in gynecological cancers [9][15] - Differentiation: New targeting approach to avoid issues faced by previous programs, focusing on the surface portion of MUC16 [15] 3. HWK-206 (SEZ6 Targeting ADC): - Target: SEZ6, relevant for small cell lung cancer and neuroendocrine tumors [20][22] - Competitive Advantage: Utilizing a biparatopic antibody for better internalization and a stable linker payload for improved safety [21][22] Clinical Development and Expectations - Initial Data Goals: Aim to demonstrate differentiation in early phase one trials, targeting a 40% overall response rate in non-small cell lung cancer and 50% in ovarian cancers [19] - Future Readouts: Anticipated data from PTK7 and MUC16 expected in 2026, with SEZ6 data projected for early to mid-2027 [23][24] Key Takeaways for Investors - Milestones: Focus on IND filings and initiation of clinical trials in the upcoming year [25] - Competitive Position: Emphasis on a best-in-class platform targeting validated but not saturated tumor antigens, providing multiple opportunities for success [25] Additional Insights - Market Positioning: Whitehawk aims to leverage its unique linker payload technology to enhance the therapeutic index of its ADCs, potentially leading to better efficacy and safety profiles compared to existing treatments [10][12] - Long-term Vision: The company is preparing to release preclinical data in 2026, which will support its strategic positioning in the competitive ADC landscape [25]
Whitehawk Therapeutics (NasdaqCM:AADI) FY Conference Transcript